Letter

Nature 453, 410-414 (15 May 2008) | doi:10.1038/nature06868; Received 14 December 2007; Accepted 25 February 2008; Published online 16 April 2008

Vascular normalization in Rgs5-deficient tumours promotes immune destruction

Juliana Hamzah1, Manfred Jugold2, Fabian Kiessling2, Paul Rigby5, Mitali Manzur1, Hugo H. Marti6, Tamer Rabie6, Sylvia Kaden3, Hermann-Josef Gröne3, Günter J. Hämmerling4, Bernd Arnold4 & Ruth Ganss1

  1. Western Australian Institute for Medical Research, UWA Centre for Medical Research, Perth, Western Australia 6000, Australia
  2. Juniorgroup Molecular Imaging, Department of Medical Physics in Radiology,
  3. Department of Cellular and Molecular Pathology, and,
  4. Department of Molecular Immunology, German Cancer Research Center, 69120 Heidelberg, Germany
  5. Centre for Microscopy, Characterisation and Analysis, The University of Western Australia, Perth, Western Australia 6000, Australia
  6. Institute of Physiology and Pathophysiology, University of Heidelberg, 69120 Heidelberg, Germany

Correspondence to: Ruth Ganss1 Correspondence and requests for materials should be addressed to R.G. (Email: ganss@waimr.uwa.edu.au).

The vasculature of solid tumours is morphologically aberrant and characterized by dilated and fragile vessels, intensive vessel sprouting and loss of hierarchical architecture1. Constant vessel remodelling leads to spontaneous haemorrhages2 and increased interstitial fluid pressure in the tumour environment3, 4. Tumour-related angiogenesis supports tumour growth and is also a major obstacle for successful immune therapy as it prevents migration of immune effector cells into established tumour parenchyma2, 5, 6. The molecular mechanisms for these angiogenic alterations are largely unknown. Here we identify regulator of G-protein signalling 5 (Rgs5) as a master gene responsible for the abnormal tumour vascular morphology in mice. Loss of Rgs5 results in pericyte maturation, vascular normalization and consequent marked reductions in tumour hypoxia and vessel leakiness. These vascular and intratumoral changes enhance influx of immune effector cells into tumour parenchyma and markedly prolong survival of tumour-bearing mice. This is the first demonstration, to our knowledge, of reduced tumour angiogenesis and improved immune therapeutic outcome on loss of a vascular gene function and establishes a previously unrecognized role of G-protein signalling in tumour angiogenesis.

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.

Extra navigation

.

naturejobs

natureproducts


ADVERTISEMENT